Generic drug maker exporting formulations directly through its own distribution network in Latin America and Africa.
Generic drug maker exporting formulations directly through its own distribution network in Latin America and Africa.
Sells through its own distribution companies across Latin America, so it keeps the distributor margin, supplying pharmacies and hospitals directly. In recent years the US sterile-injectable business, built through its Caplin Steriles unit, has become a second leg.
In one line: A niche emerging-markets generics exporter with owned distribution.
Moat: narrow (distribution, regulatory licence). Owned last-mile distribution in Latin America is unusual and hard for rivals to replicate quickly.
Headquarters: Chennai, India · Founded: 1990 · Employees: 5,455
Size Caplin Point Laboratories (CAPLIPOINT.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.70B, the 428th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,085 on 18 Nov 2026.
Performance Over six months the shares gained 2.3%, against +1.7% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 16.8% over the last twelve months (peer median +6.8%); the operating margin is 31.4% (peer median 9.9%).
Valuation It trades at 21.4× forward earnings against a peer median of 21.0× (8th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.7 points above its cost of capital (14.1% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹23.8B | ₹21.7B | ₹19.2B | ₹16.8B | ₹14.5B |
| Revenue growth | — | +13% | +15% | +15% | — |
| Gross profit | ₹11.4B | ₹9.49B | ₹8.22B | ₹6.82B | ₹5.58B |
| EBITDA | ₹8.31B | ₹7.58B | ₹6.41B | ₹5.41B | ₹4.34B |
| Net income | ₹6.89B | ₹6.41B | ₹5.36B | ₹4.57B | ₹3.76B |
| Free cash flow | n/a | ₹3.25B | ₹2.92B | ₹2.16B | ₹1.04B |
| Capital expenditure | n/a | ₹2.48B | ₹1.92B | ₹1.46B | ₹1.93B |
| Total debt | ₹46.2M | ₹46.1M | ₹50.2M | ₹19.7M | ₹54.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Caplin Point Laboratories CAPLIPOINT.NS | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% |
| NATCO Pharma NATCOPHARM.NS | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% |
| Strides Pharma Science STAR.NS | $946M | -17% | +11% | 14% | 15.9× | 17.6% |
| Marksans Pharma MARKSANS.NS | $1.43B | +36% | +24% | 20% | 23.2× | 31.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CAPLIPOINT.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.7% | -0.5% | 8th lowest of 21 |
| 6-month return | +2.3% | +1.7% | 9th highest of 20 |
| Distance from 52-week high | -30.3% | -35.8% | 8th highest of 21 |
| Revenue growth (TTM) | +16.8% | +6.8% | 8th highest of 20 |
| Operating margin | 31.4% | 9.9% | 3rd highest of 20 |
| Forward P/E | 21.4× | 21.0× | 8th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 24.3% | 14.8% | 6th most demanding of 17 |
| Growth delivered (Del g) | +15.7% | +8.7% | 5th highest of 17 |
| Hurdle (Req g minus delivered) | +8.6 pp | +1.8 pp | 6th most demanding of 17 |
| ROIC minus cost of capital | +3.7 pp | -2.7 pp | 7th highest of 21 |
| EV / EBITDA | 18.1× | 21.5× | 4th cheapest of 9 |
| Net debt / EBITDA | -1.1× | -1.1× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% | -0.2% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |